Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001415889-25-005913
Filing Date
2025-02-27
Accepted
2025-02-27 18:43:39
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 16680
2 JOINT FILING AGREEMENT ex-99-02272025_110242.htm EX-99.1 6665
  Complete submission text file 0001415889-25-005913.txt   25340
Mailing Address 855 OAK GROVE AVE. SUITE 100 MENLO PARK CA 94025
Business Address 855 OAK GROVE AVE. SUITE 100 MENLO PARK CA 94025 650-606-7910
Oruka Therapeutics, Inc. (Subject) CIK: 0000907654 (see all company filings)

EIN.: 363855489 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-51477 | Film No.: 25681634
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 530 FIFTH AVENUE, 22ND FLOOR NEW YORK NY 10036
Business Address 530 FIFTH AVENUE, 22ND FLOOR NEW YORK NY 10036 212-444-4100
Venrock Healthcare Capital Partners III, L.P. (Filed by) CIK: 0001738048 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A